| Abstract: |
Immunotherapy of cancer includes both active and adoptive, or passive, forms of immunization to target and eradicate malignant B cells in the host. Advances in the understanding of immunology and tumor-cell evasion of the host immune system, coupled with improved technologies to manipulate immune effectors and tumors, have led to a wide array of novel therapies for B-cell malignancies. As a result, investigators have proposed and tested numerous vaccine strategies able to elicit immune responses to tumor antigens. Furthermore, novel approaches to B-cell-targeted antibody therapies hold promise in advancing this line of treatment, and efficient gene transfer technologies have enabled investigators to manipulate immune effector cells to enhance antitumor activity. Significantly, an increasing number of these novel immune-based therapies are being applied to the clinical setting. Whether findings from these clinical trials, in combination with further preclinical studies, will ultimately translate into improved survival of patients with B-cell malignancies remains to be seen. Copyright © 2006 by Current Science Inc. |
| Keywords: |
unclassified drug; acute granulocytic leukemia; clinical trial; review; drug efficacy; drug safety; monotherapy; side effect; clinical trials as topic; rituximab; methodology; cd3 antigen; mouse; animal; metabolism; animals; mice; cancer immunotherapy; mantle cell lymphoma; multiple myeloma; cd40 ligand; granulocyte macrophage colony stimulating factor; combination chemotherapy; antineoplastic activity; tumor cell culture; tumor cells, cultured; transplantation; tumor antigen; acute lymphoblastic leukemia; b lymphocyte; gene transfer; monoclonal antibody; drug dose escalation; b cell lymphoma; lymphoma, b-cell; cytokine; immunology; cytokines; antibodies, monoclonal; nonhodgkin lymphoma; immunotherapy; antigens, neoplasm; cancer vaccine; cancer vaccines; cancer immunization; vaccines, synthetic; ligand; large cell lymphoma; lymphatic leukemia; tumor cell vaccine; chronic lymphatic leukemia; follicular lymphoma; intercellular adhesion molecule 1; adoptive immunotherapy; immunotherapy, adoptive; burkitt lymphoma; recombinant vaccine; b7 antigen; lymphocytoma; recombinant interleukin 2; gemtuzumab ozogamicin; keyhole limpet hemocyanin; monoclonal antibody cd28; monoclonal antibody cd3; virus vector; monoclonal antibody cd22; b cell leukemia; cancer gene therapy; antibody conjugate; immunoconjugates; active immunization; cd56 antigen; passive immunization; lymphocyte function associated antigen 1; cd20 antibody; experimental therapy; calicheamicin; immunotherapy, active; therapies, investigational; immunoglobulin idiotype; monoclonal antibody cd19; ox 40 ligand; immunoglobulin idiotypes; leukemia, b-cell
|
